Welcome to our dedicated page for Labcorp Holdings SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating when Labcorp’s diagnostics volumes jump, or spotting CMS reimbursement risks buried in a footnote, usually means scrolling through hundreds of dense pages. Investors also juggle separate documents to track drug-development backlog, litigation updates, and Labcorp insider trading Form 4 transactions — a time-consuming process.
Stock Titan solves that problem. Our AI reviews every Labcorp quarterly earnings report 10-Q filing, flags segment revenue shifts, and delivers plain-English summaries within minutes. Need real-time alerts? We stream Labcorp Form 4 insider transactions real-time so you never miss an executive’s move. From Labcorp SEC filings explained simply to detailed Labcorp earnings report filing analysis, our tools answer natural questions such as “How to read Labcorp’s 10-K?” or “What did management disclose in the latest 8-K?”
Here’s what you can explore today:
- Labcorp annual report 10-K simplified – AI-powered breakdown of diagnostics vs. drug-development margins.
- Labcorp 8-K material events explained – instant context on acquisitions, subpoenas, or changes in payer policy.
- Labcorp executive stock transactions Form 4 – monitor patterns before earnings releases.
- Labcorp proxy statement executive compensation – compare leadership pay with testing-volume performance.
Whether you’re understanding Labcorp SEC documents with AI for compliance, or scanning trendlines for your next investment thesis, Stock Titan provides:
- AI-powered summaries that demystify accounting jargon
- AGÕæÈ˹ٷ½-time EDGAR updates across all forms
- Expert insights into diagnostics pricing, payer mix, and backlog shifts
Stop hunting through PDFs and start making decisions with clarity.
Labcorp Holdings Inc. insider notice reports a proposed sale of 5,643 common shares for an aggregate market value of $1,505,439.54, to be executed through Fidelity Brokerage Services on the NYSE with an approximate sale date of 08/11/2025. The shares were acquired on 03/30/2023 by restricted stock vesting as compensation. The filing also shows the seller previously sold 6,105 shares on 05/12/2025 for gross proceeds of $1,518,496.65. The issuer's total outstanding common shares are reported as 83,100,000. By signing, the seller represents no undisclosed material adverse information and notes the compliance statements relevant to Rule 144 and Rule 10b5-1.
Labcorp Holdings (LH) � insider sale by finance executive
Form 4 filed 07/31/2025 details that SVP & Chief Accounting Officer Peter J. Wilkinson sold a total of 202 common shares on 07/29/2025 in two open-market transactions: 102 shares at $261.0102 and 100 shares at $261.035. Estimated gross proceeds equal roughly $52.7 k. Following the sales, Wilkinson’s direct ownership fell to 1,852.2194 shares. No derivative securities were reported.
The activity modestly reduces the executive’s stake and is immaterial relative to Labcorp’s share count, though investors may note it when tracking insider sentiment.